The dual c-Met/VEGFR2 inhibitor foretinib augments chemotherapy response in preclinical models of gastric cancer

被引：1
|
作者：
Awasthi, Niranjan [1 ]
Grojean, Meghan [1 ]
Monahan, Sheena [1 ]
Hassan, Sazzad [1 ]
von Holzen, Urs [1 ]
Schwarz, Margaret A. [1 ]
Schwarz, Roderich E. [1 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-5807
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5807
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models
    Guffanti, F.
    Chila, R.
    Bello, E.
    Ceriani, L.
    Zangarini, M.
    Zucchetti, M.
    Saba, C.
    Jacquet-Bescond, A.
    Pierrat, M.
    Damia, G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 110 - 110
  • [42] Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity
    Zhan, Zhengsheng
    Ai, Jing
    Liu, Qiufeng
    Ji, Yinchun
    Chen, Tiantian
    Xu, Yechun
    Geng, Meiyu
    Duan, Wenhu
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (06): : 673 - 678
  • [43] A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198
    Chia, Stephen K. L.
    Ellard, Susan
    Mates, Mihaela
    Welch, Stephen
    Mihalcioiu, Catalin Liviu Dragos
    Miller, Wilson H.
    Gelmon, Karen A.
    Lohrisch, Caroline A.
    Kumar, Vikaash
    Taylor, Sara Kristina
    Hagerman, Linda
    Eisenhauer, Elizabeth A.
    Bradbury, Penelope Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
    Eder, Joseph Paul
    Shapiro, Geoffrey I.
    Appleman, Leonard J.
    Zhu, Andrew X.
    Miles, Dale
    Keer, Harold
    Cancilla, Belinda
    Chu, Felix
    Hitchcock-Bryan, Suzanne
    Sherman, Laurie
    McCallum, Stewart
    Heath, Elisabeth I.
    Boerner, Scott A.
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2010, 16 (13) : 3507 - 3516
  • [45] Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models
    Koustas, Evangelos
    Karamouzis, Michalis V.
    Sarantis, Panagiotis
    Schizas, Dimitrios
    Papavassiliou, Athanasios G.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (18) : 10420 - 10431
  • [46] Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).
    Srinivasan, Ramaprasad
    Bottaro, Donald P.
    Choueiri, Toni K.
    Vaishampayan, Ulka N.
    Rosenberg, Jonathan E.
    Logan, Theodore
    Harzstark, Andrea Lynne
    Rini, Brian I.
    Srinivas, Sandy
    Adams, Laurel M.
    Laubscher, Kevin
    Ottesen, Lone Harild
    McDermott, David F.
    Linehan, W. Marston
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [47] Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters
    Nazari, Somayeh
    Mosaffa, Fatemeh
    Poustforoosh, Alireza
    Mortazavi, Motahareh
    Saso, Luciano
    Firuzi, Omidreza
    Moosavi, Fatemeh
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2024, 484
  • [48] TU2218 (TGF β RI/VEGFR2 dual inhibitor) maximizes the benefit of cancer immunotherapies
    Lee, Jihyun
    Kim, Nam-Hoon
    Park, Jeong Su
    Noh, Jihyun
    Bae, Sowon
    Kim, Hun-Taek
    CANCER RESEARCH, 2024, 84 (06)
  • [49] A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)
    Ross, Robert W.
    Srinivasan, Ramaprasad
    Vaishampayan, Ulka
    Bukowski, Ronald
    Rosenberg, Jonathan
    Eisenberg, Peter
    Logan, Theodore
    Srinivas, Sandhya
    Stein, Mark
    Mueller, Thomas
    Keer, Harold N.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3511S - 3511S
  • [50] Potent antitumor activity of cabozantinib, a c- MET and VEGFR2 inhibitor, in a colorectal cancer patient- derived tumor explant model
    Song, Eun-Kee
    Tai, W. M.
    Messersmith, Wells A.
    Bagby, Stacey
    Purkey, Alicia
    Quackenbush, Kevin S.
    Pitts, Todd M.
    Wang, Guoliang
    Blatchford, Patrick
    Yahn, Rachel
    Kaplan, Jeffrey
    Tan, Aik Choon
    Atreya, Chloe E.
    Eckhardt, Gail
    Kelley, Robin K.
    Venook, Alan
    Kwak, Eunice L.
    Ryan, David
    Arcaroli, John J.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (08) : 1967 - 1975
12345